Who are COSYNTROPIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Guna-Geriatrics, Melatol, Oxytocin 5 Usp Units In Dextrose 5%, Cortrosyn, Thyrogen, Acthar Gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cosyntropin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

COSYNTROPIN — Competitive Intelligence Brief

COSYNTROPIN (COSYNTROPIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adrenocorticotropic Hormone [EPC]. Area: Metabolic.

marketed Adrenocorticotropic Hormone [EPC] MC2 receptor Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

COSYNTROPIN (COSYNTROPIN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
COSYNTROPIN TARGET	COSYNTROPIN		marketed	Adrenocorticotropic Hormone [EPC]	MC2 receptor	1970-01-01
Guna-Geriatrics	BARIUM	Bracco	marketed	Adrenocorticotropic Hormone [EPC]		2019-01-01
Melatol	MELATONIN	Rad Neurim Pharmaceuticals Eec Sarl	marketed	Adrenocorticotropic Hormone [EPC]	Melatonin receptor type 1B	2007-01-01
Oxytocin 5 Usp Units In Dextrose 5%	OXYTOCIN	Fresenius Kabi	marketed	Adrenocorticotropic Hormone [EPC]	Oxytocin receptor	1980-01-01
Cortrosyn	tetracosactide	Amphastar Pharms Inc	marketed	Adrenocorticotropic Hormone [EPC]	Melanocortin receptor 4	1970-01-01
Thyrogen	THYROTROPIN ALFA	Sanofi	marketed	Adrenocorticotropic Hormone [EPC]	Thyrotropin receptor	1953-01-01
Acthar Gel	CORTICOTROPIN	Mallinckrodt Ireland	marketed	Adrenocorticotropic Hormone [EPC]	Melanocyte-stimulating hormone receptor	1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2041-07-18 — Acthar Gel · 11752199 · Method of Use · US
2043-10-27 — Acthar Gel · 12440542 · Formulation · US
2043-10-27 — Acthar Gel · 12102662 · Method of Use · US
2043-10-27 — Acthar Gel · 12233105 · Method of Use · US
2043-10-27 — Acthar Gel · 11975047 · Method of Use · US
2043-10-27 — Acthar Gel · 12324787 · Formulation · US

Sponsor landscape (Adrenocorticotropic Hormone [EPC] class)

· 2 drugs in this class
Guna spa · 2 drugs in this class
Bracco · 1 drug in this class
Fresenius Kabi · 1 drug in this class
Sanofi · 1 drug in this class
Mallinckrodt Ireland · 1 drug in this class
QUESTCOR PHARMA · 1 drug in this class
Rad Neurim Pharmaceuticals Eec Sarl · 1 drug in this class
Amphastar Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COSYNTROPIN — Competitive Intelligence Brief. https://druglandscape.com/ci/cosyntropin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab